Literature DB >> 30709509

Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

Courtney M Rowan1, Sophie Paczesny2.   

Abstract

Advances in the field of omics have led to a significant expansion in biomarkers identified for complications after hematopoietic stem cell transplantation (HSCT). Biomarkers can offer an effective method for early identification of a specific disease and can be used to guide therapies. Ongoing investigations to discover biomarkers for acute graft-versus-host disease as well as other post-HSCT complications may improve early diagnosis, prognosis, and the development of new therapeutic targets. The authors review the most recent and validated diagnostic, prognostic, predictive, and response to treatment biomarkers for early complications following HSCT consistent with 2014 NIH consensus on biomarker criteria.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Graft versus host disease; Hematopoietic stem cell transplantation; Proteomics

Mesh：

Substances：

Year:  2018        PMID： 30709509      PMCID： PMC7138508          DOI： 10.1016/j.cll.2018.10.005

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN： 0272-2712            Impact factor:   1.935


  45 in total

1.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

Authors:  Andrew C Harris; James L M Ferrara; Thomas M Braun; Ernst Holler; Takanori Teshima; John E Levine; Sung W Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R Couriel; Pavan Reddy; Sophie Paczesny
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

3.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

4.  Elafin is a biomarker of graft-versus-host disease of the skin.

Authors:  Sophie Paczesny; Thomas M Braun; John E Levine; Jason Hogan; Jeffrey Crawford; Bryan Coffing; Stephen Olsen; Sung W Choi; Hong Wang; Vitor Faca; Sharon Pitteri; Qing Zhang; Alice Chin; Carrie Kitko; Shin Mineishi; Gregory Yanik; Edward Peres; David Hanauer; Ying Wang; Pavan Reddy; Samir Hanash; James L M Ferrara
Journal:  Sci Transl Med       Date:  2010-01-06       Impact factor: 17.956

5.  Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

Authors:  Glen A Kennedy; Antiopi Varelias; Slavica Vuckovic; Laetitia Le Texier; Kate H Gartlan; Ping Zhang; Gethin Thomas; Lisa Anderson; Glen Boyle; Nicole Cloonan; Justine Leach; Elise Sturgeon; Judy Avery; Stuart D Olver; Mary Lor; Ashish K Misra; Cheryl Hutchins; A James Morton; Simon Ts Durrant; Elango Subramoniapillai; Jason P Butler; Cameron I Curley; Kelli P A MacDonald; Siok-Keen Tey; Geoffrey R Hill
Journal:  Lancet Oncol       Date:  2014-11-14       Impact factor: 41.316

6.  Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.

Authors:  Navneet S Majhail; Tejo R Challa; Daniel A Mulrooney; K Scott Baker; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

7.  Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Authors:  Victor Tkachev; Scott N Furlan; Benjamin Watkins; Daniel J Hunt; Hengqi Betty Zheng; Angela Panoskaltsis-Mortari; Kayla Betz; Melanie Brown; John B Schell; Katie Zeleski; Alison Yu; Ian Kirby; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; Duncan Casson; Phil Bland-Ward; Leslie S Kean
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

8.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Amin M Alousi; Daniel J Weisdorf; Brent R Logan; Javier Bolaños-Meade; Shelly Carter; Nancy Difronzo; Marcelo Pasquini; Steven C Goldstein; Vincent T Ho; Brandon Hayes-Lattin; John R Wingard; Mary M Horowitz; John E Levine
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

Review 9.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

10.  A biomarker panel for acute graft-versus-host disease.

Authors:  Sophie Paczesny; Oleg I Krijanovski; Thomas M Braun; Sung W Choi; Shawn G Clouthier; Rork Kuick; David E Misek; Kenneth R Cooke; Carrie L Kitko; Angela Weyand; Daniel Bickley; Dawn Jones; Joel Whitfield; Pavan Reddy; John E Levine; Samir M Hanash; James L M Ferrara
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113
View more
  7 in total

1.  Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party.

Authors:  Olaf Penack; Christophe Peczynski; Steffie van der Werf; Jürgen Finke; Arnold Ganser; Helene Schoemans; Jiri Pavlu; Riitta Niittyvuopio; Wilfried Schroyens; Leylagül Kaynar; Igor W Blau; Walter J F M van der Velden; Jorge Sierra; Agostino Cortelezzi; Gerald Wulf; Pascal Turlure; Montserrat Rovira; Zubeydenur Ozkurt; Maria J Pascual-Cascon; Maria C Moreira; Johannes Clausen; Hildegard Greinix; Rafael F Duarte; Grzegorz W Basak
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

2.  A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.

Authors:  Carina A Bäuerlein; Musga Qureischi; Zeinab Mokhtari; Paula Tabares; Christian Brede; Ana-Laura Jordán Garrote; Simone S Riedel; Martin Chopra; Simone Reu; Anja Mottok; Estibaliz Arellano-Viera; Carolin Graf; Miriam Kurzwart; Katharina Schmiedgen; Hermann Einsele; Matthias Wölfl; Paul-Gerhardt Schlegel; Andreas Beilhack
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

3.  Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort.

Authors:  Conrad Russell Y Cruz; Na Bo; Giorgos Bakoyannis; Kaylor E Wright; Elizabeth A Chorvinsky; Allison Powell; Catherine M Bollard; David Jacobsohn; Kenneth R Cooke; Christine Duncan; Robert M Krance; Paul A Carpenter; Courtney M Rowan; Sophie Paczesny
Journal:  Bone Marrow Transplant       Date:  2021-10-28       Impact factor: 5.483

4.  Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI.

Authors:  Julian C Assmann; Don E Farthing; Keita Saito; Natella Maglakelidze; Brittany Oliver; Kathrynne A Warrick; Carole Sourbier; Christopher J Ricketts; Thomas J Meyer; Steven Z Pavletic; W Marston Linehan; Murali C Krishna; Ronald E Gress; Nataliya P Buxbaum
Journal:  Blood       Date:  2021-01-07       Impact factor: 25.476

5.  Prognostic plasma biomarkers of early complications and graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Balaji Balakrishnan; Raveen Stephen Stallon Illangeswaran; Bharathi M Rajamani; Aswin Anand Pai; Infencia Xavier Raj; Daniel Zechariah Paul; Kavitha Lakshmi; Thenmozhi Mani; Ezhilpavai Mohanan; Uday Kulkarni; Anup Joseph Devasia; N A Fouzia; Anu Korula; Aby Abraham; Alok Srivastava; Vikram Mathews; Sophie Paczesny; Biju George; Poonkuzhali Balasubramanian
Journal:  EJHaem       Date:  2020-06-17

Review 6.  Biomarkers for Allogeneic HCT Outcomes.

Authors:  Djamilatou Adom; Courtney Rowan; Titilayo Adeniyan; Jinfeng Yang; Sophie Paczesny
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

Review 7.  Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Nataliya Prokopenko Buxbaum; Steven Z Pavletic
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.